Fusion Pharmaceuticals (FUSN) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free FUSN Stock Alerts $21.43 0.00 (0.00%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | americanbankingnews.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Rating of "Hold" by BrokeragesMay 10, 2024 | americanbankingnews.comWilliam Blair Weighs in on Fusion Pharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:FUSN)May 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMay 9, 2024 | marketbeat.comQ2 2024 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Boosted by William BlairFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at William Blair lifted their Q2 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will postMay 7, 2024 | investorplace.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | prnewswire.comFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesMay 1, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Sees Significant Drop in Short InterestFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 4,860,000 shares, a decline of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily trading volume, of 2,140,000 shares, the days-to-cover ratio is currently 2.3 days.May 1, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Hits New 12-Month High at $21.56Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 52-Week High at $21.56April 27, 2024 | marketbeat.comJennison Associates LLC Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Jennison Associates LLC purchased a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 301,020 shares of the company's stock, valued at approximatApril 26, 2024 | msn.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)April 25, 2024 | prnewswire.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 19, 2024 | morningstar.comFusion Pharmaceuticals Inc Ordinary SharesApril 19, 2024 | marketbeat.comFederated Hermes Inc. Acquires 202,364 Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,886,153 shares of the company's stockApril 17, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | msn.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 16, 2024 | marketbeat.comHealthInvest Partners AB Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)HealthInvest Partners AB acquired a new position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,000 shares of the company's stock, valued at approximately $1,April 16, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Earns "Hold" Rating from TD CowenTD Cowen restated a "hold" rating on shares of Fusion Pharmaceuticals in a research report on Tuesday.April 12, 2024 | marketbeat.comLeerink Partnrs Analysts Cut Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Analysts at Leerink Partnrs cut their Q1 2024 earnings estimates for Fusion Pharmaceuticals in a note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.37)April 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyApril 11, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume IncreaseFusion Pharmaceuticals (NASDAQ:FUSN) Sees Unusually-High Trading VolumeApril 9, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 4, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 12-Month High at $21.55Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.55April 3, 2024 | msn.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioApril 2, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 8.3% in MarchFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 7,920,000 shares, a decrease of 8.3% from the February 29th total of 8,640,000 shares. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is presently 3.6 days.March 28, 2024 | msn.comWhat Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for InvestorsMarch 26, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSNMarch 25, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 1-Year High at $21.32Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 52-Week High at $21.32March 24, 2024 | marketbeat.comYarbrough Capital LLC Acquires Shares of 76,872 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Yarbrough Capital LLC acquired a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 76,872 shares of the company's stock, valued at approximately $739,0March 22, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Expected to Earn FY2023 Earnings of ($1.36) Per ShareFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Equities researchers at Bloom Burton lifted their FY2023 earnings per share (EPS) estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 20th. Bloom Burton analyst D. MartinMarch 21, 2024 | marketbeat.comFY2026 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Raised by AnalystFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at Wedbush increased their FY2026 earnings estimates for shares of Fusion Pharmaceuticals in a note issued to investors on Tuesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will post earnMarch 21, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded by Bloom BurtonBloom Burton downgraded Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday.March 20, 2024 | msn.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023March 20, 2024 | markets.businessinsider.comFusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market DynamicsMarch 20, 2024 | stockhouse.comKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law FirmMarch 20, 2024 | finance.yahoo.comFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program UpdatesMarch 20, 2024 | markets.businessinsider.comUnveiling 11 Analyst Insights On Fusion PharmaceuticalsMarch 20, 2024 | marketbeat.comB. Riley Reiterates "Neutral" Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)B. Riley reissued a "neutral" rating and issued a $23.00 price objective (up previously from $13.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday.March 20, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to "Market Perform" at Leerink PartnrsLeerink Partnrs cut Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Tuesday.March 19, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMarch 19, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMarch 19, 2024 | marketbeat.comTraders Purchase High Volume of Put Options on Fusion Pharmaceuticals (NASDAQ:FUSN)Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 38,023 put options on the stock. This is an increase of approximately 10,067% compared to the typical volume of 374 put options.March 19, 2024 | marketbeat.comFusion Pharmaceuticals' (FUSN) Hold Rating Reiterated at Truist FinancialTruist Financial reaffirmed a "hold" rating and set a $21.00 price objective (up previously from $11.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday.March 19, 2024 | finance.yahoo.comHeard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion DealMarch 19, 2024 | finance.yahoo.comSuper Micro, XPeng, AstraZeneca: Trending tickersMarch 19, 2024 | finance.yahoo.comFusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca TakeoverMarch 19, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.12Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 52-Week High at $21.12March 19, 2024 | financialpost.comAstraZeneca to buy Canadian cancer treatment developer Fusion Pharmaceuticals Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (Ad)Revolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 FUSN Media Mentions By Week FUSN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FUSN News Sentiment▼0.230.56▲Average Medical News Sentiment FUSN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FUSN Articles This Week▼113▲FUSN Articles Average Week Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Inhibrx News Beam Therapeutics News Ginkgo Bioworks News ADMA Biologics News Recursion Pharmaceuticals News Neumora Therapeutics News Tarsus Pharmaceuticals News Sana Biotechnology News Apogee Therapeutics News 4D Molecular Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FUSN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
